A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs ABY 035 (Primary) ; ABY 035 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 01 Nov 2017 Planned number of patients changed from 64 to 76.
- 01 Nov 2017 Planned End Date changed from 1 Mar 2017 to 1 Jan 2018.
- 01 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2018.